Date Name Title Filing Type Shares Traded Price Total Held
Dec 30, 2020
Director, President and Chief Scientific
Director, President and Chief Scientific Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 158,079 -- --
Dec 16, 2011
Director, EVP CSO President Regeneron Re
Director, EVP CSO President Regeneron Re Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 158,079 -- 158,079
May 07, 2005
Director
Director Form 4 Other acquisition or disposition (describe transaction) 156,097 -- 157,225
May 07, 2005
Director
Director Form 4 Other acquisition or disposition (describe transaction) 156,097 -- 43,903
Dec 11, 2017
Director, Chairman of the Board
Director, Chairman of the Board Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 153,969 $21.92 483,512
Dec 11, 2017
Director, Chairman of the Board
Director, Chairman of the Board Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 153,969 -- --
Aug 16, 2017
Director, Chairman of the Board
Director, Chairman of the Board Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 153,969 $21.92 483,512
Aug 16, 2017
Director, Chairman of the Board
Director, Chairman of the Board Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 153,969 -- 153,969
Sep 18, 2013
Director, Chairman of the Board
Director, Chairman of the Board Form 4 Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 153,798 $304.38 211,115
May 24, 2019
Director, Chairman of the Board
Director, Chairman of the Board Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 153,792 $21.25 468,669

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.